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kappa index.
Results: 100 patients were analysed. With the VN 7% of patients were HR to ASA
(ARU> 550) and 41% to PFA (TO <193S). 3% were HR to aspirin with both methods.
4% were HR to ASA with the VN system but sensitive to it with the analyser PFA.
38% were sensitive to ASA with the VN test and HR with the PFA and 55% were ASA
sensitive with both methods. The Spearman correlation coefficient between both
methods of measurement of was r2= 0.09 (p = 0.35) and the Kappa index value =
0.0062 (p = 0.91).
Conclusion: 1. The prevalence of HR to ASA in type 2 diabetic patients treated with
PCI using XienceV drug-eluting stent implantation and dual antiplatelet therapy is
highly variable depending on the measurement method used. 2. There is no
concordance or correlation between both methods of measurement, and therefore its
use should be restricted to clinical research, limiting the application of these tests in
clinical practice.
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Inhibition of Platelet Aggregation by Prostaglandin E1 (PGE1) May Be
Attenuated in Diabetic Patients During Therapy with Clopidogrel
Rolf P Kreutz, Perry Nystrom, Yvonne Kreutz, Jiao Miao, Richard Kovacs, David
Flockhart, Zeruesenay Desta, Yan Jin
Indiana University School of Medicine, Indianapolis, IN
Background: Diabetes mellitus (DM) is associated with increased platelet activation
and reduced platelet inhibition by clopidogrel. PGE1 increases adenyl cyclase activity
in platelets and increases cyclic AMP concentrations. PGE1 is an endogenous platelet
inhibitor and its effects are additive to exogenous P2Y12 inhibition. The VerifyNow
(VN) P2Y12 point of care assay includes PGE1 at 22nM to suppress P2Y1 receptor
signaling along with ADP.
Methods: Subjects with established coronary artery disease and prior coronary stenting
who were taking clopidogrel 75mg daily for >14 days were enrolled (n=96). Diabetic
(n=34) were compared with non-diabetic subjects (n=62). Light transmittance
aggregometry (LTA) was performed at various concentrations of ADP with and without
the addition of PGE1, as well as VN P2Y12 assay.
Results: Residual on-treatment platelet aggregation induced by 5, 10, and 20μM ADP
was not significantly different between subjects with and without DM. Addition of
22nM and 88nM PGE1 to 20μM ADP resulted in a significant reduction of maximal
platelet aggregation (MPA). Residual platelet aggregation with PGE1 was significantly
higher in subjects with DM as compared to non-diabetics. VerifyNow P2Y12 PRU was
higher in subjects with DM as compared to non-diabetics (table). VN P2Y12 reactivity
correlated with MPA induced by ADP 20μM (r=0.69) and ADP 20μM & PGE1 22nM
(r=0.61)
Conclusion: Addition of PGE1 to ADP was associated with higher residual MPA in
subjects with DM as compared to non-diabetics. On treatment MPA induced by ADP
alone was not significantly different between subjects with and without DM measured
by LTA. Addition of PGE1 to ADP agonist platelet assays may result in a higher
proportion of subjects with DM being classified as non-responders. Impaired inhibitory
response to PGE1 may contribute to the high platelet reactivity phenotype in subjects
with DM.
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in Patients With Coronary Artery Disease
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Background: Prasugrel is associated with higher levels of platelet inhibition compared
to clopidogrel, which may result in longer times for platelet P2Y12 receptor function
to recover following drug cessation. The aim of this study was to assess the time to
recovery of platelet function in patients with coronary artery disease following
administration of a prasugrel or clopidogrel loading dose (LD).
Methods: Recovery of platelet function after LD was defined as occurring on the first
day that VerifyNow™ P2Y12 reaction units (PRU) were ≤60 below pre-drug values
and remained in this range. The percentage of subjects (n=21) who recovered over
time (3, 5, 7, 9, and 11 days) following 30 or 60 mg prasugrel or 600 mg clopidogrel
with aspirin was assessed by measurement of PRU. The relationship between inhibition
of platelet function at 24 hours post LD to time of recovery was also evaluated.
Results: Pre-drug, mean PRU was 337.6, 308.2, and 323.0 for prasugrel 60 mg,
prasugrel 30 mg, and clopidogrel 600 mg, respectively. At 24 hours post-LD, mean
PRU were lowest for prasugrel 60 mg (32.5), followed by prasugrel 30 mg (70.0), and
clopidogrel 600 mg (193.0). Recovery for all prasugrel-treated subjects occurred from
Days 5-9, while recovery for clopidogrel-treated subjects occurred from Days 3-7
(Figure 1).
Conclusion: Time for platelet function to return to baseline reflected the extent of
platelet inhibition at 24 hours post-LD. Prasugrel-treated subjects required a longer
time for recovery compared with clopidogrel.
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High On-treatment Platelet Reactivity Measured by Various Platelet Function
Tests: Is the Current VASP-PRI Cutoff Too Low?
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Hwang2, Paul A. Gurbel1
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Background: High on-treatment platelet reactivity (HPR) to ADP measured by
multiple methods has been linked to adverse post-PCI clinical event occurrence. The
correlation of HPR cutoffs is still a matter of debate, since the predictive value and
HPR group size are different depending on platelet function assays. To determine the
comparable cutpoint, we correlated cutpoints for HPR determined by various assays
in the same patient cohort.
Methods: Platelet measures [5μM ADP-induced light transmission aggregation
(LTA:5μMADP); P2Y12 reaction units by VerifyNow (PRU), and platelet reactivity
index by VASP assay (PRI)] were evaluated (n=936 pairs, cohort I) in stable CAD
patients during P2Y12 receptor inhibitor treatment. These assays also performed in
PCI-treated patients receiving standard aspirin and clopidogrel therapy (n=584, cohort
II). The HPR cutpoints were defined as LTA:5μMADP >46%, PRU >235, and PRI
>50%.
Results: In the stable CAD patients, LTA:5μMADP showed significant correlations
with PRU and PRI (r ≥0.688). In ROC curve analysis using the cutpoint of
LTA:5μMADP (>46%), the matched values of PRU and PRI were >234 (AUC 0.943,
p<0.001, sensitivity 87.3% and specificity 87.8%) and >60% (Figure A). Among PCI-
treated patients, the prevalence of HPR was highest based on PRI >50% (69%)
compared with other criteria (≤55%). The comparable values for LTA:5μMADP >46%
were PRU >235 (AUC 0.850, p<0.001, sensitivity 85.3% and specificity 70.4%) and
PRI >59% (Figure B).
Conclusion: The published cutoff values for HPR by LTA:5μMADP and PRU were
well correlated, whereas published PRI >50% cutoff value may overestimate the risk
of HPR. Updated cutoff of PRI > 60% may better stratify the risk for HPR and can be
used in future trials.
TCT-161
Anemia is a major predictor of decreased platelet response to clopidogrel
following coronary stenting
Catalin Toma, Firas E Zahr, Diego Moguillansky, Nicole Lemieux, Roy Semaan,
Rosalyn J Rapsinski, Joon S Lee, Suresh Mulukutla, Oscar C Marroquin
University of Pittsburgh Medical Center, Pittsburgh, PA
Background: A decreased response to clopidogrel as assessed by platelet aggregation
testing following percutaneous coronary interventions (PCI) is a predictor of recurrent
ischemic events. Significant intra-individual variability in platelet aggregation on repeat
testing has been reported.
Methods: To understand this variability, we examined the clinical and laboratory
elements linked to high residual platelet reactivity (HRPR) in 255 consecutive patients
tested at least 12 hrs following the PCI, using both light transmission aggregometry in
response to 5μM ADP (LTA) and the Accumetrics VerifyNow P2Y12 assay
(VNP2Y12). HRPR was defined based on previously validated cutoffs (>46% for LTA,
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